0001179110-14-010162.txt : 20140624 0001179110-14-010162.hdr.sgml : 20140624 20140611163850 ACCESSION NUMBER: 0001179110-14-010162 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140609 FILED AS OF DATE: 20140611 DATE AS OF CHANGE: 20140611 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACCELERON PHARMA INC CENTRAL INDEX KEY: 0001280600 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-649-9200 MAIL ADDRESS: STREET 1: 128 SYDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Knopf John L CENTRAL INDEX KEY: 0001586745 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36065 FILM NUMBER: 14905032 MAIL ADDRESS: STREET 1: 128 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 edgar.xml FORM 4 - X0306 4 2014-06-09 0 0001280600 ACCELERON PHARMA INC XLRN 0001586745 Knopf John L 128 SIDNEY STREET CAMBRIDGE MA 02199 1 1 0 0 CEO and President Common Stock 2014-06-09 4 S 0 3891 31.14 D 202609 D Common Stock 2014-06-09 4 S 0 6109 31.98 D 196500 D Common Stock 2014-06-09 4 S 0 2200 31.19 D 194300 D Common Stock 2014-06-09 4 S 0 2800 31.99 D 191500 D The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2013. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.76 to $31.73, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.77 to $32.32, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2014. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.76 to $31.75, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.78 to $32.22, inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4. /s/ John Quisel, as attorney-in-fact for John L. Knopf 2014-06-11